ArticleTranslational pediatrics2025
Impact of fiberoptic bronchoscopy on systemic inflammatory markers and outcomes in neonatal patients with respiratory conditions.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fiberoptic bronchoscopy is an essential tool in neonatal respiratory medicine, facilitating both diagnosis and management of complex respiratory disorders. Despite its widespread use, the procedure's impact on systemic health parameters, including inflammation, remains under-evaluated. This study investigates the effects of fiberoptic bronchoscopy on respiratory function and systemic inflammatory markers, such as the systemic immune-inflammation index (SII), in neonatal patients. Methods: A retrospective analysis was conducted on 38 neonatal patients at Anhui Provincial Children's Hospital who underwent fiberoptic bronchoscopy between January 2019 and December 2022. Clinical characteristics, respiratory outcomes, including partial pressure of oxygen (PO Results: Significant improvements were noted in blood gas parameters post-treatment, with increased PO Conclusions: Fiberoptic bronchoscopy offers significant therapeutic benefits in neonatal respiratory care beyond airway management. The identified reduction in systemic inflammation and the novel association between SII and neonatal hyperbilirubinemia offer important insights for optimizing clinical practices and patient outcomes in neonatal respiratory medicine. Further research is warranted to validate these findings and explore their implications for individualized patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.